Skip to content
Subscriber Only

Biogen Data Complicates Quest to Slow Alzheimer’s Disease

Updated on

Biogen Inc.’s experimental drug for Alzheimer’s disease failed to show a statistically significant cognitive benefit for patients on a closely watched dose, complicating the company’s quest to develop a treatment.

The findings, in data released Wednesday, leave unresolved questions about the appropriate dosage for the drug, even as Biogen moves into the next phase of trials. Investors have pinned their hopes on the treatment, driving shares up 33 percent since initial data was announced in December.